BR112015023694B1 - uso de progesterona no preparo de medicamento - Google Patents
uso de progesterona no preparo de medicamento Download PDFInfo
- Publication number
- BR112015023694B1 BR112015023694B1 BR112015023694-4A BR112015023694A BR112015023694B1 BR 112015023694 B1 BR112015023694 B1 BR 112015023694B1 BR 112015023694 A BR112015023694 A BR 112015023694A BR 112015023694 B1 BR112015023694 B1 BR 112015023694B1
- Authority
- BR
- Brazil
- Prior art keywords
- eye
- progesterone
- drug
- cranial
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790120P | 2013-03-15 | 2013-03-15 | |
| US61/790,120 | 2013-03-15 | ||
| PCT/US2014/027280 WO2014152385A2 (en) | 2013-03-15 | 2014-03-14 | Cranial delivery of pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015023694A2 BR112015023694A2 (pt) | 2017-07-18 |
| BR112015023694B1 true BR112015023694B1 (pt) | 2021-05-25 |
Family
ID=51581702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023694-4A BR112015023694B1 (pt) | 2013-03-15 | 2014-03-14 | uso de progesterona no preparo de medicamento |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9682032B2 (https=) |
| EP (1) | EP2968368B1 (https=) |
| JP (1) | JP6317805B2 (https=) |
| CN (1) | CN105188708B (https=) |
| AU (1) | AU2014239842B2 (https=) |
| BR (1) | BR112015023694B1 (https=) |
| CA (1) | CA2909490C (https=) |
| ES (1) | ES2649730T3 (https=) |
| HU (1) | HUE034886T2 (https=) |
| MX (1) | MX2015013186A (https=) |
| PT (1) | PT2968368T (https=) |
| TW (1) | TWI636785B (https=) |
| WO (1) | WO2014152385A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| US10456435B2 (en) | 2015-07-15 | 2019-10-29 | Christopher A. MCELVANY | Topical antiviral formulations and methods of using the same |
| CN110072523A (zh) * | 2016-09-07 | 2019-07-30 | 格利亚有限责任公司 | 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状 |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| CN109172580B (zh) * | 2018-09-06 | 2021-04-27 | 中山万汉制药有限公司 | 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| WO2021163253A1 (en) * | 2020-02-12 | 2021-08-19 | Glia, Llc | Progesterone combinations |
| JP2025512495A (ja) | 2022-04-12 | 2025-04-17 | シャッケルフォード・ファーマ・インコーポレーテッド | 発作性障害の治療 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766988B2 (en) * | 1998-04-21 | 2003-10-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cannabinoids as antioxidants and neuroprotectants |
| US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| US20040037895A1 (en) | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
| US20060089408A1 (en) | 2004-10-22 | 2006-04-27 | Wei Ted C Jr | Method of treating blepharospasm with a prostaglandin derivative |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| US8222292B2 (en) * | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| EP2214482A4 (en) | 2007-10-31 | 2011-08-24 | Pamela Lipkin | COMPOSITIONS OF PROSTAGLANDIN ANALOGUES AND METHODS OF TREATING EPITHELIAL STATES |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| US8236768B2 (en) | 2008-10-03 | 2012-08-07 | 3B Pharmaceuticals, Inc. | Topical antiviral formulations |
| WO2011055383A2 (en) | 2009-11-06 | 2011-05-12 | Lyka Labs Limited | Intranasal delivery to improve the performance of children suffering from dyslexia |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| PT2877184T (pt) | 2012-07-27 | 2019-12-02 | Glia Llc | Composições e tratamento para doenças e distúrbios oculares |
-
2014
- 2014-03-14 ES ES14768223.1T patent/ES2649730T3/es active Active
- 2014-03-14 WO PCT/US2014/027280 patent/WO2014152385A2/en not_active Ceased
- 2014-03-14 CA CA2909490A patent/CA2909490C/en active Active
- 2014-03-14 AU AU2014239842A patent/AU2014239842B2/en active Active
- 2014-03-14 HU HUE14768223A patent/HUE034886T2/hu unknown
- 2014-03-14 TW TW103109706A patent/TWI636785B/zh active
- 2014-03-14 MX MX2015013186A patent/MX2015013186A/es active IP Right Grant
- 2014-03-14 BR BR112015023694-4A patent/BR112015023694B1/pt active IP Right Grant
- 2014-03-14 EP EP14768223.1A patent/EP2968368B1/en active Active
- 2014-03-14 CN CN201480024402.3A patent/CN105188708B/zh active Active
- 2014-03-14 JP JP2016502396A patent/JP6317805B2/ja active Active
- 2014-03-14 US US14/777,278 patent/US9682032B2/en active Active
- 2014-03-14 PT PT147682231T patent/PT2968368T/pt unknown
-
2017
- 2017-06-20 US US15/627,894 patent/US10251835B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9682032B2 (en) | 2017-06-20 |
| JP6317805B2 (ja) | 2018-04-25 |
| CA2909490A1 (en) | 2014-09-25 |
| CN105188708A (zh) | 2015-12-23 |
| US20160030333A1 (en) | 2016-02-04 |
| CN105188708B (zh) | 2019-06-28 |
| WO2014152385A3 (en) | 2014-12-11 |
| BR112015023694A2 (pt) | 2017-07-18 |
| WO2014152385A2 (en) | 2014-09-25 |
| JP2016513691A (ja) | 2016-05-16 |
| MX2015013186A (es) | 2016-04-15 |
| TWI636785B (zh) | 2018-10-01 |
| CA2909490C (en) | 2021-07-13 |
| ES2649730T3 (es) | 2018-01-15 |
| US20170281531A1 (en) | 2017-10-05 |
| EP2968368B1 (en) | 2017-08-09 |
| EP2968368A2 (en) | 2016-01-20 |
| EP2968368A4 (en) | 2016-10-12 |
| AU2014239842A1 (en) | 2015-11-05 |
| PT2968368T (pt) | 2017-11-15 |
| HUE034886T2 (hu) | 2018-03-28 |
| HK1213202A1 (zh) | 2016-06-30 |
| US10251835B2 (en) | 2019-04-09 |
| TW201513867A (zh) | 2015-04-16 |
| AU2014239842B2 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023694B1 (pt) | uso de progesterona no preparo de medicamento | |
| JP7378781B2 (ja) | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 | |
| JP7012075B2 (ja) | 眼瞼炎の治療に使用するための医薬組成物 | |
| Krilis et al. | Vision loss and partial third nerve palsy following contralateral peribulbar anesthesia | |
| WO2023001176A1 (zh) | 一种采用长春西汀治疗近视的方法 | |
| RU2414900C1 (ru) | Способ лечения оптического неврита | |
| RU2445066C1 (ru) | Способ лечения невропатии лицевого нерва | |
| HK1213202B (zh) | 颅部的药物递送 | |
| US20260014196A1 (en) | Compositions of molecular hydrogen, oxyhydrogen and therapeutic uses thereof | |
| CA3042213C (en) | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves | |
| WO2024240216A1 (zh) | 一种有效延缓及治疗近视的药物组合物 | |
| HK40011231A (zh) | 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状 | |
| Hase et al. | Using Corneal Collagen Cross-Linking in the Treatment of Keratoconus | |
| Akheel et al. | Incidence of cervical spine injury in maxillofacial trauma | |
| Ittner | Nutritional Optic Neuropathy as Result of Topiramate-Induced Appetite Suppression | |
| Bhatt et al. | International Journal of Ayurveda and Traditional Medicine | |
| UA10777U (uk) | Спосіб лікування порушень акомодації у хворих на контузійну травму ока |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |